{
  "pmcid": "7160692",
  "sha256": "764d18e9a53707879e6befe51200dc85173c23afccfafd2bbc3f3b2740490e25",
  "timestamp_utc": "2025-11-09T16:12:09.107213+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.140000000000004,
    "reading_ease": 32.36730769230772,
    "word_count": 460
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A single-center, phase 3, randomized clinical trial was conducted at the Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy, from July 12, 2017, through March 15, 2019, among adults undergoing elective pancreaticoduodenectomy and considered at high risk for pancreatic fistula after intraoperative assessment of the fistula risk score, some of whom were randomized to undergo PG or PJ."
      },
      "Participants": {
        "score": 2,
        "evidence": "among adults undergoing elective pancreaticoduodenectomy and considered at high risk for pancreatic fistula after intraoperative assessment of the fistula risk score"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Intervention consisted of PJ or PG, both with externalized transanastomotic stent and octreotide omission."
      },
      "Objective": {
        "score": 1,
        "evidence": "To investigate whether pancreaticojejunostomy (PJ) or pancreaticogastrostomy (PG), both with externalized transanastomotic stent, is the best reconstruction method for patients at high risk of POPF after pancreaticoduodenectomy."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary end point was POPF."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "some of whom were randomized to undergo PG or PJ"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "72 were randomized undergo PG (n = 36; 20 men and 16 women; median age, 65 years [interquartile range, 23-82]) or PJ (n = 36; 26 men and 10 women; median age, 63 years [interquartile range, 35-79])"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "All analyses were performed on an intention-to-treat basis."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "There was no significant difference in the incidence of POPF between patients who underwent PG and patients who underwent PJ (18 [50.0%] vs 14 [38.9%]; P = .48), but for patients who developed a POPF, the mean (SD) average complication burden was lower for those who underwent PJ than for those who underwent PG (0.25 [0.13] vs 0.39 [0.17]; P = .04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "patients who underwent PG presented with a significantly higher incidence of Clavien-Dindo grade 3 or higher morbidity than those who underwent PJ (17 [47.2%] vs 8 [22.2%]; P = .047)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov Identifier: NCT03212196"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}